Investing.com - Avadel Pharma reported on Monday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Avadel Pharma announced earnings per share of $0.49 on revenue of $10.09M. Analysts polled by Investing.com anticipated EPS of $-0.17 on revenue of $8.23M.
Avadel Pharma shares are up 10.73% from the beginning of the year, still down 38.03% from its 52 week high of $13.49 set on April 27. They are under-performing the Nasdaq which is up 22.72% from the start of the year.
Avadel Pharma shares lost 1.32% in pre-market trade following the report.
Avadel Pharma follows other major Healthcare sector earnings this month
Avadel Pharma's report follows an earnings beat by J&J on July 16, who reported EPS of $1.67 on revenue of $18.34B, compared to forecasts EPS of $1.49 on revenue of $17.61B.
Roche Holding ADR had beat expectations on July 23 with second quarter EPS of $1.45 on revenue of $15.27B, compared to forecast for EPS of $1.42 on revenue of $15.43B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar